

# Baris Turkbey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7589865/publications.pdf>

Version: 2024-02-01

267  
papers

18,591  
citations

14644

66  
h-index

14736

127  
g-index

275  
all docs

275  
docs citations

275  
times ranked

10683  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology, 2019, 76, 340-351.	0.9	1,270
2	Comparison of MR/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390.	3.8	1,267
3	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England Journal of Medicine, 2020, 382, 917-928.	13.9	515
4	Prostate Cancer: Value of Multiparametric MR Imaging at 3 T for Detection-Histopathologic Correlation. Radiology, 2010, 255, 89-99.	3.6	441
5	Multiparametric 3T Prostate Magnetic Resonance Imaging to Detect Cancer: Histopathological Correlation Using Prostatectomy Specimens Processed in Customized Magnetic Resonance Imaging Based Molds. Journal of Urology, 2011, 186, 1818-1824.	0.2	440
6	Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy. European Urology, 2013, 64, 713-719.	0.9	436
7	Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy Improves Cancer Detection Following Transrectal Ultrasound Biopsy and Correlates With Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2011, 186, 1281-1285.	0.2	408
8	Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. Nature Communications, 2020, 11, 4080.	5.8	405
9	Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology, 2016, 280, 793-804.	3.6	398
10	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. European Urology, 2013, 64, 544-552.	0.9	383
11	Is Apparent Diffusion Coefficient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images?. Radiology, 2011, 258, 488-495.	3.6	372
12	Federated learning for predicting clinical outcomes in patients with COVID-19. Nature Medicine, 2021, 27, 1735-1743.	15.2	300
13	Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology, 2015, 277, 741-750.	3.6	296
14	Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Computer Aided Surgery, 2008, 13, 255-264.	1.8	272
15	Overview of Dynamic Contrast-Enhanced MRI in Prostate Cancer Diagnosis and Management. American Journal of Roentgenology, 2012, 198, 1277-1288.	1.0	248
16	Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. Journal of Urology, 2012, 188, 2152-2157.	0.2	227
17	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology, 2020, 296, 76-84.	3.6	207
18	Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer, 2013, 119, 3359-3366.	2.0	205

#	ARTICLE	IF	CITATIONS
19	Prostate Cancer: Can Multiparametric MR Imaging Help Identify Patients Who Are Candidates for Active Surveillance?. <i>Radiology</i> , 2013, 268, 144-152.	3.6	201
20	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. <i>European Urology</i> , 2019, 75, 385-396.	0.9	200
21	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendationsâ€”A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 648-655.	0.9	190
22	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. <i>Journal of Urology</i> , 2012, 188, 1157-1163.	0.2	188
23	What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. <i>Radiology</i> , 2018, 286, 186-195.	3.6	188
24	Imaging Localized Prostate Cancer: Current Approaches and New Developments. <i>American Journal of Roentgenology</i> , 2009, 192, 1471-1480.	1.0	181
25	Utility of Multiparametric Magnetic Resonance Imaging Suspicion Levels for Detecting Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 1721-1727.	0.2	171
26	Accuracy and agreement of PIRADSV2 for prostate cancer mpMRI: A multireader study. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 579-585.	1.9	170
27	Intravoxel incoherent motion MR imaging for prostate cancer: An evaluation of perfusion fraction and diffusion coefficient derived from different $\alpha$ value combinations. <i>Magnetic Resonance in Medicine</i> , 2013, 69, 553-562.	1.9	169
28	Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy. <i>Journal of Urology</i> , 2014, 191, 1749-1754.	0.2	167
29	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. <i>Radiology</i> , 2019, 292, 464-474.	3.6	162
30	Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 706-712.	0.2	152
31	Localized Prostate Cancer Detection with $^{18}\text{F}$ FACBC PET/CT: Comparison with MR Imaging and Histopathologic Analysis. <i>Radiology</i> , 2014, 270, 849-856.	3.6	141
32	A Magnetic Resonance Imagingâ€”Based Prediction Model for Prostate Biopsy Risk Stratification. <i>JAMA Oncology</i> , 2018, 4, 678.	3.4	141
33	A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. <i>Radiology</i> , 2019, 290, 709-719.	3.6	140
34	Federated semi-supervised learning for COVID region segmentation in chest CT using multi-national data from China, Italy, Japan. <i>Medical Image Analysis</i> , 2021, 70, 101992.	7.0	140
35	Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: Correlation with whole-mount histopathology. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 1443-1448.	1.9	138
36	Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e1-202.e7.	0.8	133

#	ARTICLE	IF	CITATIONS
37	Diagnostic value of biparametric magnetic resonance imaging (<scp>MRI</scp>) as an adjunct to prostate-specific antigen (<scp>PSA</scp>)-based detection of prostate cancer in men without prior biopsies. BJU International, 2015, 115, 381-388.	1.3	128
38	Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. Ca-A Cancer Journal for Clinicians, 2016, 66, 326-336.	157.7	128
39	Multiparametric MRI in prostate cancer management. Nature Reviews Clinical Oncology, 2014, 11, 346-353.	12.5	127
40	Prospective Evaluation of PI-RADS, Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. Journal of Urology, 2017, 198, 583-590.	0.2	127
41	Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. Radiology, 2017, 285, 859-869.	3.6	126
42	In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?. BJU International, 2015, 115, 562-570.	1.3	125
43	<sup>11</sup> C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation. Journal of Nuclear Medicine, 2012, 53, 538-545.	2.8	119
44	Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. Journal of Urology, 2016, 196, 690-696.	0.2	116
45	D'Amico Risk Stratification Correlates With Degree of Suspicion of Prostate Cancer on Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2011, 185, 815-820.	0.2	113
46	Current status of magnetic resonance imaging (<scp>MRI</scp>) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU International, 2014, 114, 641-652.	1.3	111
47	Multiparametric MRI and prostate cancer diagnosis and risk stratification. Current Opinion in Urology, 2012, 22, 310-315.	0.9	105
48	Multiparametric magnetic resonance imaging (<scp>MRI</scp>) and subsequent <scp>MRI</scp>/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers. BJU International, 2014, 114, E43-E49.	1.3	103
49	A method for correlating <i>in vivo</i> prostate magnetic resonance imaging and histopathology using individualized magnetic resonance -based molds. Review of Scientific Instruments, 2009, 80, 104301.	0.6	102
50	Intra- and interreader reproducibility of PI-RADSv2: A multireader study. Journal of Magnetic Resonance Imaging, 2019, 49, 1694-1703.	1.9	102
51	Discrete Deformable Model Guided by Partial Active Shape Model for TRUS Image Segmentation. IEEE Transactions on Biomedical Engineering, 2010, 57, 1158-1166.	2.5	100
52	Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look. American Journal of Roentgenology, 2016, 206, 1179-1183.	1.0	92
53	Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU International, 2012, 110, E783-8.	1.3	91
54	Computer Aided-Diagnosis of Prostate Cancer on Multiparametric MRI: A Technical Review of Current Research. BioMed Research International, 2014, 2014, 1-11.	0.9	90

#	ARTICLE	IF	CITATIONS
55	Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. Journal of Urology, 2017, 197, 640-646.	0.2	90
56	Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathologyâ€”Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?. Journal of Urology, 2018, 199, 976-982.	0.2	89
57	The Current State of MR Imagingâ€”targeted Biopsy Techniques for Detection of Prostate Cancer. Radiology, 2017, 285, 343-356.	3.6	88
58	Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. Journal of Urology, 2017, 197, 327-334.	0.2	84
59	PSMA PET and Radionuclide Therapy in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 522-535.	2.5	82
60	Automated prostate cancer detection using $T_2$ -weighted and high $b$ -value diffusion-weighted magnetic resonance imaging. Medical Physics, 2015, 42, 2368-2378.	1.6	81
61	Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. Urology, 2016, 88, 125-134.	0.5	81
62	Prostate MRI and 3D MR Spectroscopy: How We Do It. American Journal of Roentgenology, 2010, 194, 1414-1426.	1.0	80
63	PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. American Journal of Roentgenology, 2021, 216, 3-19.	1.0	76
64	Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. American Journal of Roentgenology, 2019, 212, 1197-1205.	1.0	75
65	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. European Urology Oncology, 2020, 3, 145-167.	2.6	75
66	Can Magnetic Resonance-Ultrasound Fusion Biopsy Improve Cancer Detection in Enlarged Prostates?. Journal of Urology, 2013, 190, 2020-2025.	0.2	73
67	The Kinetics and Reproducibility of $^{18}$ F-Sodium Fluoride for Oncology Using Current PET Camera Technology. Journal of Nuclear Medicine, 2012, 53, 1175-1184.	2.8	71
68	Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. Journal of the National Cancer Institute, 2016, 108, djw039.	3.0	68
69	Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. European Radiology, 2018, 28, 4407-4417.	2.3	68
70	Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. Journal of Urology, 2018, 200, 1041-1047.	0.2	66
71	Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. European Urology, 2020, 78, 371-378.	0.9	66
72	Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation. Oncotarget, 2018, 9, 33804-33817.	0.8	65

#	ARTICLE	IF	CITATIONS
73	Accelerated $T_2$ mapping for characterization of prostate cancer. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 1400-1406.	1.9	62
74	Artificial intelligence at the intersection of pathology and radiology in prostate cancer. <i>Diagnostic and Interventional Radiology</i> , 2019, 25, 183-188.	0.7	62
75	Use of Patient-specific MRI-based Prostate Mold for Validation of Multiparametric MRI in Localization of Prostate Cancer. <i>Urology</i> , 2012, 79, 233-239.	0.5	61
76	Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. <i>Diagnostic and Interventional Radiology</i> , 2014, 20, 293-298.	0.7	60
77	Clinical Implications of a Multiparametric Magnetic Resonance Imaging Based Nomogram Applied to Prostate Cancer Active Surveillance. <i>Journal of Urology</i> , 2015, 193, 1943-1949.	0.2	60
78	Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 578-586.	2.0	58
79	A Phase I Dosing Study of Ferumoxyl for MR Lymphography at 3 T in Patients With Prostate Cancer. <i>American Journal of Roentgenology</i> , 2015, 205, 64-69.	1.0	57
80	Clinical impact of PSMA-based $^{18}F$ -DCFPET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 4-11.	3.3	57
81	The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 194, 105-111.	0.2	56
82	DCE MRI of prostate cancer. <i>Abdominal Radiology</i> , 2016, 41, 844-853.	1.0	56
83	Documenting the location of prostate biopsies with image fusion. <i>BJU International</i> , 2011, 107, 53-57.	1.3	55
84	Identification of Threshold Prostate Specific Antigen Levels to Optimize the Detection of Clinically Significant Prostate Cancer by Magnetic Resonance Imaging/Ultrasound Fusion Guided Biopsy. <i>Journal of Urology</i> , 2014, 192, 1642-1649.	0.2	55
85	Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging. <i>Radiology</i> , 2015, 276, 479-489.	3.6	53
86	Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer. <i>Radiology</i> , 2018, 288, 485-491.	3.6	53
87	Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. <i>BJU International</i> , 2012, 110, E694-700.	1.3	52
88	Fully Automated Prostate Segmentation on MRI: Comparison With Manual Segmentation Methods and Specimen Volumes. <i>American Journal of Roentgenology</i> , 2013, 201, W720-W729.	1.0	52
89	Deep Learning-Based Artificial Intelligence for PI-RADS Classification to Assist Multiparametric Prostate MRI Interpretation: A Development Study. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1499-1507.	1.9	52
90	Recent advances in image-guided targeted prostate biopsy. <i>Abdominal Imaging</i> , 2015, 40, 1788-1799.	2.0	48

#	ARTICLE	IF	CITATIONS
91	Deep dense multi-path neural network for prostate segmentation in magnetic resonance imaging. International Journal of Computer Assisted Radiology and Surgery, 2018, 13, 1687-1696.	1.7	47
92	Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. BJU International, 2012, 110, 1642-1647.	1.3	45
93	Multiparametric Magnetic Resonance Imaging and Image-Guided Biopsy to Detect Seminal Vesicle Invasion by Prostate Cancer. Journal of Endourology, 2014, 28, 1283-1289.	1.1	45
94	Comparison of magnetic resonance imaging and ultrasound (<sup>MRI</sup> fusion-guided prostate biopsies obtained from axial and sagittal approaches. BJU International, 2015, 115, 772-779.	1.3	45
95	Lymph Node Staging in Prostate Cancer. Current Urology Reports, 2015, 16, 30.	1.0	45
96	Prostate MR Imaging for Posttreatment Evaluation and Recurrence. Radiologic Clinics of North America, 2018, 56, 263-275.	0.9	45
97	Imaging Prostate Cancer: An Update on Positron Emission Tomography and Magnetic Resonance Imaging. Current Urology Reports, 2010, 11, 180-190.	1.0	44
98	Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer. Topics in Magnetic Resonance Imaging, 2016, 25, 139-147.	0.7	44
99	Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 473-491.	0.8	44
100	Quality of Prostate MRI: Is the PI-RADS Standard Sufficient?. Academic Radiology, 2021, 28, 199-207.	1.3	44
101	Determination of disease severity in COVID-19 patients using deep learning in chest X-ray images. Diagnostic and Interventional Radiology, 2021, 27, 20-27.	0.7	44
102	The Role of MRI in Active Surveillance for Prostate Cancer. Current Urology Reports, 2015, 16, 42.	1.0	43
103	Radiomics and radiogenomics of prostate cancer. Abdominal Radiology, 2019, 44, 2021-2029.	1.0	43
104	Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer. JAMA Oncology, 2017, 3, 1415.	3.4	42
105	Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 30.e1-30.e8.	0.8	42
106	Active surveillance for prostate cancer. Current Opinion in Oncology, 2012, 24, 243-250.	1.1	41
107	Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia. Diagnostic and Interventional Radiology, 2014, 20, 229-233.	0.7	41
108	Imaging of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 147-155.	0.8	41

#	ARTICLE	IF	CITATIONS
109	A Prospective Comparison of <sup>18</sup> F-Sodium Fluoride PET/CT and PSMA-Targeted <sup>18</sup> F-DCFBC PET/CT in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1665-1671.	2.8	40
110	PIRADS 2.0: what is new?. <i>Diagnostic and Interventional Radiology</i> , 2015, 21, 382-384.	0.7	38
111	Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges. <i>Radiology</i> , 2017, 285, 728-743.	3.6	38
112	Optimal high b-value for diffusion weighted MRI in diagnosing high risk prostate cancers in the peripheral zone. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 125-131.	1.9	38
113	Prostate Cancer: Top Places Where Tumors Hide on Multiparametric MRI. <i>American Journal of Roentgenology</i> , 2015, 204, W449-W456.	1.0	37
114	PIRADS: Past, present, and future. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 33-53.	1.9	37
115	Prostate cancer detection from multi-institution multiparametric MRIs using deep convolutional neural networks. <i>Journal of Medical Imaging</i> , 2018, 5, 1.	0.8	37
116	PET/CT imaging of renal cell carcinoma with <sup>18</sup> F-VM4-037: a phase II pilot study. <i>Abdominal Radiology</i> , 2016, 41, 109-118.	1.0	35
117	Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. <i>Translational Andrology and Urology</i> , 2018, 7, 831-843.	0.6	35
118	Quantitative Prostate MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1632-1645.	1.9	35
119	Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy. <i>Abdominal Imaging</i> , 2015, 40, 2557-2565.	2.0	34
120	Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. <i>Translational Andrology and Urology</i> , 2017, 6, 413-423.	0.6	34
121	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 9567-9578.	2.3	34
122	Detection of prostate cancer in multiparametric MRI using random forest with instance weighting. <i>Journal of Medical Imaging</i> , 2017, 4, 024506.	0.8	33
123	Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. <i>Radiology</i> , 2017, 285, 147-156.	3.6	33
124	Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 425.e1-425.e6.	0.8	32
125	Magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised MRI-based moulds. <i>BJU International</i> , 2013, 112, 508-516.	1.3	31
126	All over the map: An interobserver agreement study of tumor location based on the PIRADSV2 sector map. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 482-490.	1.9	31

#	ARTICLE	IF	CITATIONS
127	Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?. World Journal of Urology, 2019, 37, 235-241.	1.2	31
128	The Role of Image Guided Biopsy Targeting in Patients with Atypical Small Acinar Proliferation. Journal of Urology, 2015, 193, 473-478.	0.2	30
129	Evaluation of Prostate Cancer with PET/MRI. Journal of Nuclear Medicine, 2016, 57, 111S-116S.	2.8	29
130	Multicenter Multireader Evaluation of an Artificial Intelligenceâ€œBased Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. American Journal of Roentgenology, 2020, 215, 903-912.	1.0	29
131	Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?. Journal of Urology, 2022, 207, 95-107.	0.2	29
132	Does Abstinence From Ejaculation Before Prostate MRI Improve Evaluation of the Seminal Vesicles?. American Journal of Roentgenology, 2016, 207, 1205-1209.	1.0	28
133	A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications, 2020, 11, 837.	5.8	28
134	Functional and molecular imaging of localized and recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 48-59.	3.3	26
135	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	1.8	26
136	Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSV2 and International Society of Urological Pathology Systems. American Journal of Roentgenology, 2018, 211, W33-W41.	1.0	26
137	Impact of bowel preparation with Fleetâ€™sâ„¢ enema on prostate MRI quality. Abdominal Radiology, 2020, 45, 4252-4259.	1.0	26
138	Magnetic resonance imaging of localized prostate cancer: coming of age in the psa era. Diagnostic and Interventional Radiology, 2011, 18, 34-45.	0.7	26
139	A urologistâ€™s perspective on prostate cancer imaging: past, present, and future. Abdominal Radiology, 2016, 41, 805-816.	1.0	25
140	The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 254.e15-254.e21.	0.8	25
141	Prostate MR Imaging for Posttreatment Evaluation and Recurrence. Urologic Clinics of North America, 2018, 45, 467-479.	0.8	24
142	Detecting Prostate Cancer with Deep Learning for MRI: A Small Step Forward. Radiology, 2019, 293, 618-619.	3.6	24
143	Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup> F-DCFPyL PET/CT with Comparison to Multiparametric MRI. Radiology, 2020, 296, 564-572.	3.6	24
144	Role of multiparametric prostate MRI in the management of prostate cancer. World Journal of Urology, 2021, 39, 651-659.	1.2	24

#	ARTICLE	IF	CITATIONS
145	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. <i>European Urology Oncology</i> , 2022, 5, 176-186.	2.6	24
146	Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy. <i>Journal of Urology</i> , 2019, 201, 84-90.	0.2	24
147	<sup>18</sup> F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, 735-740.	0.7	23
148	Risk stratification of prostate cancer utilizing apparent diffusion coefficient value and lesion volume on multiparametric MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 610-616.	1.9	23
149	Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 341.e1-341.e7.	0.8	23
150	Data Augmentation and Transfer Learning to Improve Generalizability of an Automated Prostate Segmentation Model. <i>American Journal of Roentgenology</i> , 2020, 215, 1403-1410.	1.0	23
151	Does focal incidental <sup>18</sup> F-FDG PET/CT uptake in the prostate have significance?. <i>Abdominal Imaging</i> , 2015, 40, 3222-3229.	2.0	22
152	Prospective Evaluation of <sup>18</sup> F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. <i>American Journal of Roentgenology</i> , 2020, 215, 652-659.	1.0	22
153	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	3.2	22
154	Advancement of MR and PET/MR in Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 536-543.	2.5	21
155	Imaging the High-risk Prostate Cancer Patient: Current and Future Approaches to Staging. <i>Urology</i> , 2018, 116, 3-12.	0.5	21
156	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. <i>Diagnostic and Interventional Radiology</i> , 2018, 24, 46-53.	0.7	21
157	A Cascaded Deep Learning-Based Artificial Intelligence Algorithm for Automated Lesion Detection and Classification on Biparametric Prostate Magnetic Resonance Imaging. <i>Academic Radiology</i> , 2022, 29, 1159-1168.	1.3	21
158	Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. <i>Radiology</i> , 2022, 304, 342-350.	3.6	21
159	Prostate Cancer Diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling. <i>Journal of Urology</i> , 2016, 196, 62-67.	0.2	20
160	Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, S453-S461.	0.6	20
161	Improving detection of prostate cancer foci via information fusion of MRI and temporal enhanced ultrasound. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020, 15, 1215-1223.	1.7	20
162	Image-guided focal therapy for prostate cancer. <i>Diagnostic and Interventional Radiology</i> , 2014, 20, 492-497.	0.7	20

#	ARTICLE	IF	CITATIONS
163	Ruling out clinically significant prostate cancer with negative multi-parametric MRI. International Urology and Nephrology, 2018, 50, 7-12.	0.6	19
164	Deep learning-based artificial intelligence applications in prostate MRI: brief summary. British Journal of Radiology, 2022, 95, 20210563.	1.0	19
165	Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort. Journal of Urology, 2016, 195, 1737-1743.	0.2	18
166	Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 1326-1335.	1.9	18
167	Positron emission tomography (PET) radiotracers for prostate cancer imaging. Abdominal Radiology, 2020, 45, 2165-2175.	1.0	18
168	A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy. Turkish Journal of Urology, 2019, 45, 357-365.	1.3	18
169	Deep learning-based artificial intelligence for prostate cancer detection at biparametric MRI. Abdominal Radiology, 2022, 47, 1425-1434.	1.0	18
170	Magnetic Resonance Sentinel Lymph Node Imaging of the Prostate with Gadofosveset Trisodium-Albumin. Academic Radiology, 2015, 22, 646-652.	1.3	17
171	Ferumoxylol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. American Journal of Roentgenology, 2020, 214, 105-113.	1.0	17
172	Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection. American Journal of Roentgenology, 2020, 215, 1098-1103.	1.0	17
173	A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis. European Radiology, 2021, 31, 4386-4389.	2.3	17
174	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e235-e245.	1.8	16
175	Imaging of distant metastases of prostate cancer. Medical Oncology, 2018, 35, 148.	1.2	16
176	<i>RadioGraphics</i> Update: PI-RADS Version 2.1-”A Pictorial Update. Radiographics, 2020, 40, E33-E37.	1.4	16
177	Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 787.e17-787.e21.	0.8	16
178	Prostate Biopsy for the Interventional Radiologist. Journal of Vascular and Interventional Radiology, 2014, 25, 675-684.	0.2	15
179	Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance. European Urology Oncology, 2021, 4, 227-234.	2.6	14
180	Magnetic Resonance Lymphography of the Thoracic Duct after Interstitial Injection of Gadofosveset Trisodium: A Pilot Dosing Study in a Porcine Model. Lymphatic Research and Biology, 2014, 12, 32-36.	0.5	13

#	ARTICLE	IF	CITATIONS
181	Role of Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer. Current Urology Reports, 2014, 15, 387.	1.0	13
182	Evaluating the Role of mpMRI in Prostate Cancer Assessment. Expert Review of Medical Devices, 2016, 13, 129-141.	1.4	13
183	PI-RADSV2: How we do it. Journal of Magnetic Resonance Imaging, 2017, 46, 11-23.	1.9	13
184	PI-RADS v2: Current standing and future outlook. Turkish Journal of Urology, 2018, 44, 189-194.	1.3	13
185	Evaluating the size criterion for PI-RADSV2 category 5 upgrade: is 15Åmm the best threshold?. Abdominal Radiology, 2018, 43, 3436-3444.	1.0	13
186	Novel Imaging in Detection of Metastatic Prostate Cancer. Current Oncology Reports, 2019, 21, 31.	1.8	13
187	CT and clinical assessment in asymptomatic and pre-symptomatic patients with early SARS-CoV-2 in outbreak settings. European Radiology, 2021, 31, 3165-3176.	2.3	13
188	Differentiating Transition Zone Cancers From Benign Prostatic Hyperplasia by Quantitative Multiparametric Magnetic Resonance Imaging. Journal of Computer Assisted Tomography, 2016, 40, 218-224.	0.5	12
189	Should Hypoechoic Lesions on Transrectal Ultrasound Be Sampled During Magnetic Resonance Imaging-targeted Prostate Biopsy?. Urology, 2017, 105, 113-117.	0.5	12
190	Pilot study for supervised target detection applied to spatially registered multiparametric MRI in order to non-invasively score prostate cancer. Computers in Biology and Medicine, 2018, 94, 65-73.	3.9	12
191	A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI). Academic Radiology, 2019, 26, 5-14.	1.3	12
192	PI-QUAL, a New System for Evaluating Prostate Magnetic Resonance Imaging Quality: Is Beauty in the Eye of the Beholder?. European Urology Oncology, 2020, 3, 620-621.	2.6	12
193	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. IEEE Access, 2021, 9, 87531-87542.	2.6	12
194	Future Perspectives and Challenges of Prostate MR Imaging. Radiologic Clinics of North America, 2018, 56, 327-337.	0.9	11
195	Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques. Radiation Oncology, 2021, 16, 32.	1.2	11
196	Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. Radiology, 2021, 299, 613-623.	3.6	11
197	Artificial Intelligence for Automated Cancer Detection on Prostate MRI: Opportunities and Ongoing Challenges, From the <i>AJR</i> Special Series on AI Applications. American Journal of Roentgenology, 2022, 219, 188-194.	1.0	11
198	Quantitative Image Quality Comparison of Reduced- and Standard-Dose Dual-Energy Multiphase Chest, Abdomen, and Pelvis CT. Tomography, 2017, 3, 114-122.	0.8	10

#	ARTICLE	IF	CITATIONS
199	MR lymphangiography with intradermal gadofosveset and human serum albumin in mice and primates. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 691-697.	1.9	9
200	Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification. <i>International Urology and Nephrology</i> , 2016, 48, 1445-1452.	0.6	9
201	The Problems with the Kappa Statistic as a Metric of Interobserver Agreement on Lesion Detection Using a Third-reader Approach When Locations Are Not Prespecified. <i>Academic Radiology</i> , 2018, 25, 1325-1332.	1.3	9
202	Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review. <i>Translational Andrology and Urology</i> , 2020, 9, 1415-1427.	0.6	9
203	Use of multiparametric magnetic resonance imaging (mpMRI) in localized prostate cancer. <i>Expert Review of Medical Devices</i> , 2020, 17, 435-442.	1.4	9
204	Development of a 3D CNN-based AI Model for Automated Segmentation of the Prostatic Urethra. <i>Academic Radiology</i> , 2022, 29, 1404-1412.	1.3	9
205	Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers. <i>Cancers</i> , 2022, 14, 2996.	1.7	9
206	Multiparametric MRI in Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-3.	0.9	8
207	Engaging and educating patients in prostate imaging via social media. <i>Abdominal Radiology</i> , 2016, 41, 798-798.	1.0	8
208	Ferumoxylol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates. <i>Acta Radiologica</i> , 2016, 57, 1396-1401.	0.5	8
209	Factors Impacting Performance and Reproducibility of PI-RADS. <i>Canadian Association of Radiologists Journal</i> , 2021, 72, 337-338.	1.1	8
210	Role of mpMRI in Benign Prostatic Hyperplasia Assessment and Treatment. <i>Current Urology Reports</i> , 2020, 21, 55.	1.0	8
211	Algorithms applied to spatially registered multi-parametric MRI for prostate tumor volume measurement. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 119-132.	1.1	8
212	Correlation of prostate tumor eccentricity and Gleason scoring from prostatectomy and multi-parametric-magnetic resonance imaging. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 4235-4244.	1.1	8
213	Clinical Application of Artificial Intelligence in Positron Emission Tomography: Imaging of Prostate Cancer. <i>PET Clinics</i> , 2022, 17, 137-143.	1.5	8
214	A decade in image-guided prostate biopsy. <i>Nature Reviews Urology</i> , 2014, 11, 611-612.	1.9	7
215	Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. <i>Urology Practice</i> , 2014, 1, 13-21.	0.2	7
216	A Case of In-Bore Transperineal MRI-Guided Prostate Biopsy of a Patient with Ileal Pouch-Anal Anastomosis. <i>Case Reports in Urology</i> , 2015, 2015, 1-3.	0.1	7

#	ARTICLE	IF	CITATIONS
217	Prostate Imaging Reporting and Data System Version 2 for MRI of Prostate Cancer: Can We Do Better?. American Journal of Roentgenology, 2019, 212, 1244-1252.	1.0	7
218	Assessment of the compliance with minimum acceptable technical parameters proposed by PI-RADS v2 guidelines in multiparametric prostate MRI acquisition in tertiary referral hospitals in the Republic of Turkey. Diagnostic and Interventional Radiology, 2020, 25, 421-427.	0.7	7
219	Rapid perceptual processing in two- and three-dimensional prostate images. Journal of Medical Imaging, 2020, 7, 1.	0.8	7
220	Recent Advancements in CT and MR Imaging of Prostate Cancer. Seminars in Nuclear Medicine, 2022, 52, 365-373.	2.5	7
221	Artificial Intelligence-based Tumor Segmentation in Mouse Models of Lung Adenocarcinoma. Journal of Pathology Informatics, 2022, 13, 100007.	0.8	7
222	Precision management of localized prostate cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 505-515.	0.4	6
223	The Importance of Quality in Prostate MRI. Seminars in Roentgenology, 2021, 56, 384-390.	0.2	6
224	Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 729.e1-729.e6.	0.8	6
225	Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1096-1108.	1.1	6
226	Development and testing quantitative metrics from multi-parametric magnetic resonance imaging that predict Gleason score for prostate tumors. Quantitative Imaging in Medicine and Surgery, 2021, 12, 0-0.	1.1	6
227	Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI. European Radiology, 2022, 32, 2221-2223.	2.3	6
228	When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion of Prostate Cancer. Journal of Urology, 2019, 201, 943-949.	0.2	5
229	PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance. Journal of Urology, 2020, 204, 1229-1235.	0.2	5
230	MRI characterization of the dynamic effects of 5 $\alpha$ -reductase inhibitors on prostate zonal volumes. Canadian Journal of Urology, 2013, 20, 7002-7.	0.0	5
231	Birth of a standard: MET-RADS-P for metastatic prostate cancer. Nature Reviews Urology, 2016, 13, 568-570.	1.9	4
232	Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer. Urology, 2020, 144, 164-170.	0.5	4
233	What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer. American Journal of Roentgenology, 2020, 214, 1211-1219.	1.0	4
234	Quantitative Characterization of the Prostatic Urethra Using MRI: Implications for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia. Academic Radiology, 2021, 28, 664-670.	1.3	4

#	ARTICLE	IF	CITATIONS
235	PI-RADSV2.1: Current status. Turkish Journal of Urology, 2021, 47, S45-S48.	1.3	4
236	Practice Patterns and Challenges of Performing and Interpreting Prostate MRI: A Survey by the Society of Abdominal Radiology Prostate Diseaseâ€”Focused Panel. American Journal of Roentgenology, 2021, 216, 952-959.	1.0	4
237	Using Imaging to Predict Treatment Response in Genitourinary Malignancies. European Urology Focus, 2018, 4, 804-817.	1.6	3
238	Prostate Magnetic Resonance Imaging: Lesion Detection and Local Staging. Annual Review of Medicine, 2019, 70, 451-459.	5.0	3
239	18F-fluciclovine PET or PSMA PET for prostate cancer imaging?. Nature Reviews Urology, 2020, 17, 9-10.	1.9	3
240	Advances in Prostate Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 407-414.	0.6	3
241	Interactive Feature Space ExplorerÂ© for multi-modal magnetic resonance imaging. Magnetic Resonance Imaging, 2015, 33, 804-815.	1.0	2
242	Reply to â€œStandardizing Biparametric MRI to Simplify and Improve Prostate Imaging Reporting and Data System, Version 2, in Prostate Cancer Managementâ€”. American Journal of Roentgenology, 2016, 207, W76-W76.	1.0	2
243	Better Image Quality for Diffusion-weighted MRI of the Prostate Using Deep Learning. Radiology, 2022, , 212078.	3.6	2
244	Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. Journal of Urology, 2022, 208, 90-99.	0.2	2
245	Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2022, , .	0.2	2
246	Incorporating imaging into personalized medicine for the detection of prostate cancer. Pharmacological Research, 2016, 114, 163-165.	3.1	1
247	Current Role of Magnetic Resonance Imaging in Prostate Cancer. Current Radiology Reports, 2017, 5, 1.	0.4	1
248	Can fast bi-parametric MRI help prostate cancer detection in biopsy naive men?. Chinese Clinical Oncology, 2020, 9, 40-40.	0.4	1
249	Can BOLD fMRI Demonstrate Early Response to Chemoembolization in HCCs?. Academic Radiology, 2021, 28 Suppl 1, S20-S21.	1.3	1
250	Editorial Comment: MRI for Benign Prostatic Hyperplasiaâ€”An Underutilized Imaging Opportunity. American Journal of Roentgenology, 2021, , 13.	1.0	1
251	The need for standardization of reporting in prostate MRI. Nature Reviews Urology, 2021, 18, 195-196.	1.9	1
252	Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, e17567-e17567.	0.8	1

#	ARTICLE	IF	CITATIONS
253	Imaging in Localized Prostate Cancer. , 2016, , 91-99.		0
254	Role of Magnetic Resonance Imaging in Prostate Cancer Assessment. Current Clinical Urology, 2017, , 161-176.	0.0	0
255	Diffusion-Weighted Imaging in Magnetic Resonance Imaging of the Prostate. , 2018, , 167-178.		0
256	Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76:329-40. European Urology, 2019, 76, e79.	0.9	0
257	Apical periurethral transition zone lesions: MRI and histology findings. Abdominal Radiology, 2020, 45, 3258-3264.	1.0	0
258	Submucosal Enhancing Stripe: An Important Contrast-enhanced MRI Feature for Staging of Rectal Cancers. Radiology, 2021, 298, 102-103.	3.6	0
259	AI-Assisted CT as a Clinical and Research Tool for COVID-19. Frontiers in Artificial Intelligence, 2021, 4, 590189.	2.0	0
260	Artificial Intelligence in Prostate Imaging. Advances in Clinical Radiology, 2021, 3, 15-22.	0.1	0
261	Beyond the AJR: "Comparison of Multiparametric Magnetic Resonance Imaging" Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial"; American Journal of Roentgenology, 2021, , 1-1.	1.0	0
262	Tracked Foley catheter for motion compensation during fusion image-guided prostate procedures: a phantom study. European Radiology Experimental, 2020, 4, 24.	1.7	0
263	Molecular Imaging of Prostate Cancer. , 2020, , 171-190.		0
264	Local staging of prostate cancer with imaging: can hybrid imaging be the solution?. Translational Andrology and Urology, 2020, 9, 834-836.	0.6	0
265	Focal Laser Ablation for Prostate Cancer. , 2021, , 215-226.		0
266	Successful SBRT for post-brachytherapy prostate recurrence and penile bulb metastasis. Advances in Radiation Oncology, 2021, , 100860.	0.6	0
267	Role of MRI in Prostate Cancer Assessment. , 2021, , 81-94.		0